ArticleJournal of cardiothoracic surgery2026
The SGLT2 inhibitor dapagliflozin alleviates ventricular remodeling and apoptosis after myocardial infarction by inhibiting the TGF-β1 and MAPK pathways.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHeart failure and ventricular remodeling are the major cardiac injuries after myocardial infarction (MI). Sodium‒glucose cotransporter 2 (SGLT2) inhibitors have been shown to be effective at alleviating heart failure and improving patient outcomes and quality of life. However, whether SGLT2 has the same effect on myocardial infarction is unclear. The aim of this study was to elucidate the efficacy and underlying mechanisms of dapagliflozin on the outcome of myocardial infarction.
methodsA porcine model of myocardial infarction was established via percutaneous coronary intervention with a balloon-dilated catheter and treated with dapagliflozin (DPG), an SGLT2 inhibitor, for 8 weeks. The biochemical indices of pig blood were determined. M-mode echocardiography was performed to determine cardiac structure and function. HE staining, Masson staining and TUNEL were used to detect myocardial fibrosis and apoptosis. The expression of target proteins in signal transduction pathways was determined by Western blotting.
resultsDPG treatment ameliorated myocardial hypertrophy and fibrosis and increased collagen synthesis and apoptosis induced by myocardial infarction in pigs. Moreover, DPG inhibited the activation of the TGF-β1 and MAPK signaling pathways.
conclusionDPG can effectively reduce ventricular remodeling and myocardial cell apoptosis after myocardial infarction. DPG inhibits the TGF-β1 and MAPK pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.